Company’s work in personalized immunotherapies honored for 3rd consecutive year
Opexa Therapeutics, Inc., announced that it has been named one of the “Top Projects to Watch” for the third consecutive year. A panel of independent experts recognized the biopharmaceutical company for its work in the development of personalized immunotherapies for autoimmune disorders, such as multiple sclerosis (MS) and neuromyelitis optica (NMO).
Opexa was among eight companies whose efforts in six therapeutic areas were selected as top projects, out of hundreds of compounds considered by the panel for their potential as products. The selection was announced at the recent Therapeutic Area Partnerships meeting in Boston, where Opexa’s President and CEO Neil K. Warma presented an overview of his company.
“Selected companies… represent what our committees consider among the most attractive opportunities the industry has to offer,” Marc Wortman, Editorial Director at Therapeutic Area Partnerships, said in a press release. “Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability. As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners, and acquirers.”
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Keep up to date with the news and information we provide
by signing up by clicking here
.===================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews